This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Madhusudan, S. Articles by Harris, A. L. Search for Related Content PubMed PubMed Citation Articles by Madhusudan, S. Articles by Harris, A. L.

A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor Inhibitor in Patients with Metastatic Breast Cancer

¹ Cancer Research United Kingdom Medical Oncology Unit, University of Oxford, The Churchill, Oxford Radcliffe Hospitals, Headington, Oxford, United Kingdom; and ² Cancer Research United Kingdom Translational Oncology Laboratory, Barts and The London, Queen Mary’s School of Medicine and Dentistry, London, United Kingdom

Purpose: Tumor necrosis factor (TNF) is a key player in the tumor microenvironment and is involved in the pathogenesis of breast cancer. Etanercept is a recombinant human soluble p75 TNF receptor that binds to TNF- and renders it biologically unavailable. In the current study, we sought to determine the toxicity, biological activity, and therapeutic efficacy of Etanercept in metastatic breast cancer.

Experimental Design: We initiated a Phase II, nonrandomized, open-labeled study in patients with progressive metastatic breast cancer refractory to conventional therapy (Phase I toxicity data were available in patients with rheumatoid arthritis). Etanercept was administered subcutaneously at a dose of 25 mg twice weekly until disease progression.

Results: Sixteen patients were recruited [median age 53 years (range, 34 to 74)]. A total of 141.6 weeks of therapy was administered (median of 8.1 weeks). Seven patients received 12 weeks of therapy. The most common side effects were injection site reactions (6), fatigue (5), loss of appetite (2), nausea (1), headache (1), and dizziness (1). Brief period of disease stabilization was seen in 1 patient lasting for 16.4 weeks. Immunoreactive TNF- was elevated within 24 hours of therapy and persisted until the end of treatment (days 7, 28, 56, and 84). Phytohemagglutinin stimulates the production of interleukin-6 and CCL2 in peripheral blood cells, and the ability of Etanercept to modulate this response was assessed in a cytokine release assay. A consistent decrease in interleukin-6 and CCL2 level was seen compared with pretreatment values in serial blood samples (days 1, 7, 28, 56, and 84).

Conclusions: Our study shows the safety and biological activity of Etanercept in breast cancer and provides data to assess pharmacodynamic endpoints of different schedules of Etanercept and combinations with chemotherapy or other biological therapies.

This article has been cited by other articles:

				M. Hurtado-Nedelec, S. Chollet-Martin, P. Nicaise-Roland, S. Grootenboer-Mignot, R. Ruimy, O. Meyer, and G. Hayem Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome Rheumatology, August 1, 2008; 47(8): 1160 - 1167. [Abstract] [Full Text] [PDF]

				E. R. Brown, K. A. Charles, S. A. Hoare, R. L. Rye, D. I. Jodrell, R. E. Aird, R. Vora, U. Prabhakar, M. Nakada, R. E. Corringham, et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-{alpha} inhibitor, in patients with advanced cancer Ann. Onc., July 1, 2008; 19(7): 1340 - 1346. [Abstract] [Full Text] [PDF]

				A. H. Miller, S. Ancoli-Israel, J. E. Bower, L. Capuron, and M. R. Irwin Neuroendocrine-Immune Mechanisms of Behavioral Comorbidities in Patients With Cancer J. Clin. Oncol., February 20, 2008; 26(6): 971 - 982. [Abstract] [Full Text] [PDF]

				J. E. Bower Behavioral Symptoms in Patients With Breast Cancer and Survivors J. Clin. Oncol., February 10, 2008; 26(5): 768 - 777. [Abstract] [Full Text] [PDF]

				P. M. McGowan, B. M. Ryan, A. D.K. Hill, E. McDermott, N. O'Higgins, and M. J. Duffy ADAM-17 Expression in Breast Cancer Correlates with Variables of Tumor Progression Clin. Cancer Res., April 15, 2007; 13(8): 2335 - 2343. [Abstract] [Full Text] [PDF]

				J. Zhang, M. A. Warren, S. F. Shoemaker, and M. M. Ip NF{kappa}B1/p50 Is Not Required for Tumor Necrosis Factor-Stimulated Growth of Primary Mammary Epithelial Cells: Implications for NF{kappa}B2/p52 and RelB Endocrinology, January 1, 2007; 148(1): 268 - 278. [Abstract] [Full Text] [PDF]

				H. Yang, M. Bocchetta, B. Kroczynska, A. G. Elmishad, Y. Chen, Z. Liu, C. Bubici, B. T. Mossman, H. I. Pass, J. R. Testa, et al. TNF-{alpha} inhibits asbestos-induced cytotoxicity via a NF-{kappa}B-dependent pathway, a possible mechanism for asbestos-induced oncogenesis PNAS, July 5, 2006; 103(27): 10397 - 10402. [Abstract] [Full Text] [PDF]

				S. Madhusudan, S. R. Muthuramalingam, J. P. Braybrooke, S. Wilner, K. Kaur, C. Han, S. Hoare, F. Balkwill, and T. S. Ganesan Study of Etanercept, a Tumor Necrosis Factor-Alpha Inhibitor, in Recurrent Ovarian Cancer J. Clin. Oncol., September 1, 2005; 23(25): 5950 - 5959. [Abstract] [Full Text] [PDF]

				P. Allavena, M. Signorelli, M. Chieppa, E. Erba, G. Bianchi, F. Marchesi, C. O. Olimpio, C. Bonardi, A. Garbi, A. Lissoni, et al. Anti-inflammatory Properties of the Novel Antitumor Agent Yondelis (Trabectedin): Inhibition of Macrophage Differentiation and Cytokine Production Cancer Res., April 1, 2005; 65(7): 2964 - 2971. [Abstract] [Full Text] [PDF]